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1. From Farm to laboratory: comparing the legislation
Directives set out general regulations applicable across the European 
Union; which Member States transpose into national law as appropriate. A 
number of Directives govern the use of animals by humans. Animals kept or 
bred for farming fall under Directive 98/58/EC: Protection of Animals Kept 
for Farming Purposes and the use of animals for research is regulated by 
Directive 63/2010/EU: Protection of Animals Used for Scientific Purposes. 
Every year nearly 360 million pigs; sheep; goats and cattle as well as 
several billion poultry are killed in EU slaughterhouses. The European 
fur industry adds another 25 million animals to the figure. Hatcheries kill 
around 330 million day-old-chicks which are surplus to the egg industry. 
The control of contagious diseases may also require the killing of thousands 
to millions of animals (European Commission 2016).
Almost 11.5 million animals are used for research in the EU; includ-
ing those for basic biological research; genetic modification experiments; 
toxicology testing and research and development of drugs (European 
Commission 2011). The most used species are mice; rats and fish; totalling 
around 10 million; as well as over 17.000 dogs; almost 4.000 cats and more 
than 6.000 primates (European Commission 2011). The economic value of 
livestock farming in the EU represents an annual value of €149 billion. The 
use of experimental animals is estimated to an annual value of €930 million 
(European Commission 2012). 
The focus of both Directives is on the keeping animals for use by 
humans with the intention of promoting animal welfare. However; both 
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are led by economics; with Directive 98/58/EC aiming at “eliminating 
distortions of competition” (Council Directive 98/58/EC 1998) and Direc-
tive 2010/63/EU setting out to harmonise laboratory animal standards to 
reduce disparities between Member States which are “liable to constitute 
barriers to trade in products and substances” (Directive 63/2010/EU 2010).
Both Directives present conflicting ideals about the treatment of ani-
mals; by making statements on the importance of animal welfare; whilst 
setting standards for a life which inevitably involves suffering. Directive 
98/58/EC states how animals shall not be kept unless it is “without detri-
mental effect on its health or welfare” (Council Directive 98/58/EC 1998). 
However; the minimum conditions for intensive factory farming is detri-
mental to health and welfare by nature; the routine use of antibiotics for 
example is a widespread practice to prevent the spread of disease (Landers 
et al. 2012). Directive 2010/63/EU affirms how animals “have an intrin-
sic value which must be respected” and recognises animals as “sentient 
creatures”; whilst licensing their use as tools in research which is known to 
cause pain; suffering and distress (Directive 63/2010/EU 2010). 
One of the main differences between the laboratory and farm animal 
directives is how they perceive animal use. Directive 98/58/EC makes no 
comment on intrinsic value of animals; or any desire to put an end to the 
use of animals in food production (Council Directive 98/58/EC 1998). 
Directive 2010/63/EU however; acknowledges the use of animals in 
research to be ethically objectionable; noting the capacity of animals to feel 
pain; fear and distress whilst outlining a desire to end their use through the 
promotion and application of advanced scientific methodology; the 3Rs; 
specifically replacement (Directive 63/2010/EU 2010). 
1.1. The difference in perception allows a legislative move away
 from animal research 
This subtle but important difference in the spirit of Directive 2010/63/
EU; allows for opportunities and potential for the eventual elimination of 
animal research; through a combination of review; assessment and imple-
mentation of non-animal methods. Recital 10 states:
While it is desirable to replace the use of live animals in procedures by other 
methods not entailing the use of live animals; the use of live animals contin-
ues to be necessary to protect human and animal health and the environ-
ment. However; this Directive represents an important step towards achiev-
ing the final goal of full replacement of procedures on live animals for scientific 
and educational purposes as soon as it is scientifically possible to do so. To 
that end; it seeks to facilitate and promote the advancement of alternative 
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approaches. It also seeks to ensure a high level of protection for animals that 
still need to be used in procedures. This Directive should be reviewed regu-
larly in light of evolving science and animal-protection measures. (Directive 
63/2010/EU 2010; emphasis added)
This encompasses the main tools available within the Directive for a phase 
out of animal testing: promotion and advancement of alternative methods; 
review of the legislation and consideration of scientific evolution; all legiti-
mised by the final goal of full replacement of animals. 
The principles of replacement; reduction and refinement are out-
lined in Article 4 of Directive 2010/63/EU. Member States are required 
to ensure that “wherever possible; a scientifically satisfactory method or 
testing strategy; not entailing the use of live animals; shall be used instead 
of a procedure” (Directive 63/2010/EU 2010). Reduction and refinement 
(keeping the number of animal used in a procedure to a minimum and 
keeping pain; suffering or harm to animals to a minimum; respectively) are 
provisions which attend to animal welfare; but do not contribute to the aim 
of full replacement of animals in research. 
Article 47 of Directive 2010/63/2010 stipulates further obligations for 
the Commission and Member States to “contribute to the development 
and validation of alternative approaches which could provide the same or 
higher levels of information as those obtained in procedures using animals” 
(Directive 63/2010/EU 2010); to set up laboratories for validation of alter-
native methods and ensure dissemination of these approaches.
2. rationale For ending animal use
The use of animals in scientific procedures with the intention of benefit-
ing humans is fundamentally flawed due to “species differences”. Animal 
tests are an unreliable way to predict effects in humans because each spe-
cies responds differently to substances. For example; penicillin is a useful 
antibiotic for people but it is lethal when tested in guinea pigs (Hamre et 
al. 1943). The breast cancer drug tamoxifen was designed as an oral contra-
ceptive. It is in rats; but in women it has the opposite effect. It is now used 
in the treatment of breast cancer; despite causing cancer in rats in some 
studies (Read 1988). The cancer drug 6-azauridine can be used in humans 
for long periods; but in dogs small doses produce potentially lethal results 
in a few days (Weatherall 1982). Phenylbutazone works through the body 
slowly in humans; but in dogs it disappears in hours (Lees et al. 2004). The 
list of substances and their effects in different species is immeasurable. 
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Furthermore; the reliance on data from animals can produce unex-
pected adverse reactions in people in clinical trials; even fatal outcomes. 
TGN1412  – an experimental drug was given to human volunteers and 
caused life-threatening reactions; yet monkeys were given doses 500 times 
higher than the human volunteers and no side effects had been seen (Duff 
2006).
Most recently; the French BIA 10-2474 drug trial; despite animal toxic-
ity testing; went fatally wrong when given to human volunteers – one died; 
four showed evidence of brain damage (Callaway and Butler 2016). The 
substance had been tested on mice; rats; rabbits; dogs and monkeys for 
toxic effects on various organs as well as reproductive toxicity. Monkeys 
were given doses approx 75 times that given to the human volunteers (fig-
ures calculated from BIAL – Portela & Ca S.A. 2015; calculations available 
on request).
There are also ethical concerns held for animals used in research. The 
public are less accepting of the use of companion animals; such as dogs; 
cats and horses; as well as animals which are more like humans; such as 
monkeys. 75% of the UK public agree that more should be done to find 
alternatives to animals in research (Ipsos MORI 2016). In the political 
arena; there is also a strong desire to end the use of some of our closest 
relatives in research. 433 MEPs signed Written Declaration 40/2007 calling 
for a timetable to be set to end all experiments on non-human primates in 
Europe; at that time; the most supported Written Declaration on an animal 
protection issue ever (Animal Defenders International 2007). 
Within various industries; non-animal technologies have been iden-
tified emerging areas with a potential to drive economic growth. This 
includes recognition of concerns about the predictivity of animal testing; 
acknowledgement of the scepticism of some researchers to move away from 
animal research; and the potential to improve safety and efficacy testing of 
chemicals and pharmaceuticals (Innovate UK 2015).
3. advancing replacement oF animals
Directive 63/2010/EU is progressive in that in includes provisions to 
advance the replacement of animals as described in Article 58:
The Commission shall review this Directive by 10 November 2017; taking 
into account advancements in the development of alternative methods not 
entailing the use of animals; in particular of non-human primates; and shall 
propose amendments; where appropriate. The Commission shall; where 
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appropriate; and in consultation with the Member States and stakehold-
ers; conduct periodic thematic reviews of the replacement; reduction and 
refinement of the use of animals in procedures; paying specific attention to 
non-human primates; technological developments; and new scientific and 
animal-welfare knowledge. (Directive 63/2010/EU 2010; emphasis added)
The first paragraph recognises the need for legislation to be able to keep 
up with changes in science and pace of technological advancements. The-
matic review; cited in the second paragraph; has the potential to provide a 
mechanism by which areas of animal research; or particular experiments; 
can be replaced with alternatives. But this must be effectively implemented 
by the Commission.
3.1. Advancing thematic review 
The concept of thematic review provides a clear mechanism to keep pace 
with advances in technological and scientific progress; and move toward 
the ultimate goal of replacing animals in research. This can be achieved if 
the European Commission acts on Article 58 and implements a system of 
biennial thematic review; allowing relevant stakeholders to identify specific 
candidate areas of research for consideration and review. 
The European Commission could coordinate Europe-wide activity; 
with Member States initiating projects. It is suggested that submissions 
relating to replacement of animals are prioritised over reduction or refine-
ment; due to the former being able to contribute to the phasing out of 
animals use; the goal of this Directive. The process of conducting thematic 
review could be carried out using existing mechanisms for gathering data 
and scientific opinion; via a specific scientific committee. Proposals for the 
European Commission to carry out thematic review are as follows:
Step 1: Commission call for candidate submission
Following a call by the Commission; stakeholders should submit informa-
tion on their rationale for proposed area of research for review; including 
referenced information such as:
 • Area or method proposed for review. 
 • Estimates of number of animals involved and outline the typical procedures.
 • An outline of the rationale for the proposal including; but not restricted 
to: available non-animal methods; evidence of unreliability of the model 
or lack of proven benefits or utility; severe suffering of animals with little 
or no demonstrable benefits; methods no longer used in certain countries; 
including outside the EU; consideration of evolving public opinion in par-
ticular research areas or using certain species.
 • Identifying barriers and a demonstration of how these may be overcome. 
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Step 2: Candidate selection
The Commission should select a minimum of four candidates for replace-
ment and one candidate for reduction or refinement to go forward for fur-
ther review. The complexity and work required for each review may vary 
greatly from subject to subject; so the number of topics put forward for 
review may vary. 
Step 3: In-depth review and research
The selected candidates would be given to a “Thematic Review Commit-
tee” for further review. For each candidate; the Committee will study each 
proposed aspect of the rationale for review; gather further information and 
make decisions on the potential steps towards replacement which can be 
made.
Ultimately this process would result in the publication of a report by the 
Thematic Review Committee with recommendations for each of the candi-
dates; including proposals for establishing timetables for action.
Step 4: Report and establishment of timetables or dates for replacement/aban-
donment
Taking into account all of the information gathered over the course of the 
review; the Commission should establish a timetable of actions on each 
review topic. Depending on the status of the non-animal method; the nature 
of barriers and assessment of the actual value of the animal use; the timetable 
may span months or years; or may permit immediate implementation. The 
strategy may also include a number of courses of action; such as re-diverting 
funding; legislative changes or amendments and notifying Member States 
about the unacceptability of the particular use of animals. 
4. the importance oF ending animal use 
In comparison to Directive 98/58/EC; Directive 63/2010/EU has scope for 
making progress towards the goal of ending animal use in this area. Replac-
ing the use of animals with alternative methods is important for reliable 
science; human health; economic reasons and because of ethical concerns 
which the public hold about subjecting animals to experiments. With the 
global recognition that animal agriculture is a major cause of ill health; early 
death and climate change; Directive 98/58/EC should emphasise plant 
food production and emulate the provisions included within Directive 
63/2010/EU towards the final goal of ending animal use replacing animal 
food production with healthier plant options.
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